Filtered By:
Condition: Diabetes
Management: Hospitals
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 528 results found since Jan 2013.
PCSK9 inhibitors: a major advance in cholesterol-lowering drug therapy
Every so often a medical advance comes along that rewrites the script for treating a disease or condition. After today’s announcements of impressive results of a new type of cholesterol-lowering drug, that scenario just might happen in the next few years.
The new drugs, called PCSK9 inhibitors, are monoclonal antibodies. They target and inactivate a specific protein in the liver. Knocking out this protein, called proprotein convertase subtilisin kexin 9, dramatically reduces the amount of harmful LDL cholesterol circulating in the bloodstream. Lower LDL translates into healthier arteries and fewer heart attacks, stro...
Source: New Harvard Health Information - March 15, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Drugs and Supplements Heart Health Medical Research alirocumab cholesterol evolocumab PCSK9 inhibitors Source Type: news
Tight blood sugar control in type 2 diabetes linked to fewer heart attacks and strokes
Diabetes damages every part of the body, from the brain to the feet. High blood sugar, the hallmark of diabetes, wreaks havoc on blood vessels. It makes sense that keeping blood sugar under control should prevent diabetes-related damage — but how low to push blood sugar is an open question.
A study published in today’s issue of The New England Journal of Medicine (NEJM) provides reassuring evidence that so-called tight blood sugar control is good for the heart and circulatory system.
“Tight blood sugar control represents a new age of diabetes care,” says Dr. David Nathan, professor of medicine at Harvar...
Source: New Harvard Health Information - June 4, 2015 Category: Consumer Health News Authors: Urmila Parlikar Tags: Diabetes blood sugar blood sugar control Source Type: news
Studies support broader use of cholesterol-lowering statins
The latest guidelines used to determine who should take a cholesterol-lowering statin to prevent heart disease appear to be more accurate and cost-efficient than the previous guidelines. That’s according to two studies led by Harvard researchers, both published in this week’s Journal of the American Medical Association.
For many years, the main deciding factor in who needed to take a statin was the level of an individual’s harmful low-density lipoprotein cholesterol (LDL). Updated guidelines published in 2013 by the American College of Cardiology and the American Heart Association moved away from LDL and ...
Source: New Harvard Health Information - July 16, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements cholesterol high cholesterol statins Source Type: news
EPMA-World Congress 2015
Table of contents
A1 Predictive and prognostic biomarker panel for targeted application of radioembolisation improving individual outcomes in hepatocellular carcinoma
Jella-Andrea Abraham, Olga Golubnitschaja
A2 Integrated market access approach amplifying value of “Rx-CDx”
Ildar Akhmetov
A3 Disaster response: an opportunity to improve global healthcare
Russell J. Andrews, Leonidas Quintana
A4 USA PPPM: proscriptive, profligate, profiteering medicine-good for 1 % wealthy, not for 99 % unhealthy
Russell J. Andrews
A5 The role of ...
Source: EPMA Journal - May 8, 2016 Category: Global & Universal Source Type: research
A multiparameter model predicting in-hospital mortality in malignant cerebral infarction
Abstract: The early identification of patients with large hemisphere infarctions (LHIs) at risk of fatal brain edema may result in better outcomes. A quantitative model using parameters obtained at admission may be a predictor of in-hospital mortality from LHI.
This prospective study enrolled all patients with LHI involving>50% of the middle cerebral artery (MCA) admitted to our neurological intensive care unit within 48 hours of symptom onset. Early clinical and radiographic parameters and the baseline CHADS2 score (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke [double weight]) w...
Source: Medicine - July 1, 2017 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research
Under Affordable Care Act, Americans have had more preventive care for heart health, UCLA study finds
By reducing out-of-pocket costs for preventive treatment, the Affordable Care Act appears to have encouraged more people to have health screenings related to their cardiovascular health,a UCLA study found. Comparing figures from 2006 through 2013, researchers found that more people were screened for diabetes, high cholesterol, cigarette use and high blood pressure — all risk factors for heart disease — after the ACA was implemented than before.But the research, published in the peer-reviewed American Journal of Managed Care, also revealed a disparity between men and women in one key area. Although more men who are at r...
Source: UCLA Newsroom: Health Sciences - November 23, 2017 Category: Universities & Medical Training Source Type: news
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
Publication date: Available online 6 December 2017 Source:The Lancet Diabetes & Endocrinology Author(s): M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Peter Öhman, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular...
Source: The Lancet Diabetes and Endocrinology - December 6, 2017 Category: Endocrinology Source Type: research
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
Publication date: Available online 2 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Marc P Bonaca, J Antonio Gutierrez, Christopher Cannon, Robert Giugliano, Michael Blazing, Jeong-Gun Park, Jennifer White, Andrew Tershakovec, Eugene BraunwaldSummaryBackgroundPolyvascular disease and type 2 diabetes are each associated with increased cardiovascular risk, but whether these risks are additive is unknown. In this exploratory analysis of a randomised trial, we explored the long-term cardiovascular risk associated with polyvascular disease, type 2 diabetes, and their combination in patients with acute corona...
Source: The Lancet Diabetes and Endocrinology - November 3, 2018 Category: Endocrinology Source Type: research
Fish Oil and Vitamin D Supplements May Not Help Prevent Heart Attacks and Cancer, Study Says
There’s good evidence that fish oil supplements may lower the risk of second heart events — like a heart attack or stroke — in people with heart disease, but few rigorous studies have investigated whether the supplement can help people to lower their risk of having a heart event in the first place. And while some data suggests that people with lower levels of vitamin D tend to have higher rates of heart disease and cancer, the evidence isn’t solid.
Now, a new study published in the New England Journal of Medicine and presented at the annual meeting of the American Heart Association offers more findi...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs Source Type: news
Depression Is More than a Stigma
Manoj K. Pandey is Lecturer in Economics, Australian National University; Vani S. Kulkarni is Lecturer in Sociology, University of Pennsylvania; and Raghav Gaiha is (Hon. ) Professorial Research Fellow, Global Development Institute, University of ManchesterBy Manoj K. Pandey, Vani S. Kulkarni and Raghav GaihaCanberra, Philadelphia and Manchester, Mar 20 2019 (IPS) Depression is often distinguished from other non-communicable diseases or NCDs (e.g., cancer, diabetes, cardio-vascular diseases, hypertension) because of the stigma attached to it. Among other consequences, those suffering from depression are often denied access...
Source: IPS Inter Press Service - Health - March 20, 2019 Category: International Medicine & Public Health Authors: Manoj K. Pandey - and Raghav Gaiha Tags: Featured Global Headlines Health Human Rights TerraViva United Nations Women's Health Source Type: news
The importance of extended working hours for work-related injuries
Discussion of Reduction Strategies and Behavioral Responses from a North American Perspective. Euro J Trans Infra Res. 2002;2(4).
21. POPM.gov [internet] Policy, Data, Oversight. Available from: https://www.opm.gov/policy-data-oversight/pay-leave/work-sched ules/fact-sheets/alternative-work-schedules-compressed-work-schedules/. Accessed June 30, 2021.
22. Kivimäki M, Nyberg ST, Batty GD, Fransson EI, Heikkilä K, Alfredsson L, et al. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. Lancet. 2012;380(9852):1491-7. https://doi.org/10.1016/S0140-6736(12)60...
Source: Scandinavian Journal of Work, Environment and Health - August 11, 2021 Category: Occupational Health Tags: Editorial Source Type: research
Measuring Ambulation, Motor, and Behavioral Outcomes with Poststroke Fluoxetine in Tanzania: The Phase II MAMBO Trial
Am J Trop Med Hyg. 2021 Dec 6:tpmd210653. doi: 10.4269/ajtmh.21-0653. Online ahead of print.ABSTRACTWe test the safety of fluoxetine postischemic stroke in sub-Saharan Africa. Adults with acute ischemic stroke, seen <14 days since new-onset motor deficits, were enrolled from November 2019 to October 2020 in a single-arm, open-label phase II trial of daily fluoxetine 20 mg for 90 days at Muhimbili National Hospital, Dar es Salaam, Tanzania. The primary outcome was safety with secondary outcomes of medication adherence and tolerability. About 34 patients were enrolled (11 were female; mean age 52.2 years, 65% < 60 year...
Source: The American Journal of Tropical Medicine and Hygiene - December 6, 2021 Category: Tropical Medicine Authors: Farrah Mateen Emmanuel Massawe Notburga Mworia Seif Ismail Dylan Rice Andre Vogel Boniface Kapina Novath Mukyanuzi Deus Buma Jef Gluckstein Michael Wasserman Susan Fasoli Faraja Chiwanga Kigocha Okeng'o Source Type: research
